Subcutaneous Ocrelizumab for the Treatment of Relapsing Forms of Multiple Sclerosis: A Budget Impact Model

Authors:

Abstract
No abstract available
Funding Information
  • Roche Italia

This publication has 33 references indexed in Scilit: